YOLFTbeta
Krystal Biotech Inc

Krystal Biotech Inc

KRYS · NASDAQ · Healthcare / Biotechnology

305.23USD-0.45 (-0.15%)

Price History

Full chart

Market Stats

Previous Close305.68
Open305.68
Day Range300.39 – 306.73
52-Week Range192.52 – 382.54
Volume109.69K
Market Cap9.84B
P/E (TTM)41.64
Forward P/E47.85
EPS7.98
Dividend Yield0.00%
Beta0.50
50-Day Avg337.46
200-Day Avg308.53

About

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Krish S. Krishnan M.B.A., M.S.
  • Employees295
  • Headquarters2100 Wharton Street, Pittsburgh, PA, United States, 15203, USA
  • Websitehttps://www.krystalbio.com

Leadership

  • Mr. Krish S. Krishnan M.B.A., M.S.Founder, Chairman, President & CEO · b. 1965
  • Ms. Suma M. KrishnanFounder, President of R&D and Director · b. 1965
  • Ms. Kathryn A. Romano CPAExecutive VP & Chief Accounting Officer · b. 1982
  • Mr. John C. ThomasEVP, General Counsel & Corporate Secretary · b. 1974
  • Mr. John KarakkalVice President of North American Sales & Marketing
  • Dr. Stephane Paquette Ph.D.Senior Vice President of Corporate Development
  • Mr. Josh SuskinSenior Director & Head of US Human Resources
  • Mr. Laurent GouxExecutive VP & Head of International · b. 1975
  • Dr. David Chien M.D.Senior Vice President of Clinical Development
  • Ms. Christine WilsonSenior VP & Head of US Commercial

Financials

Income Statement

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue001.03M000050.70M290.51M389.13M
Growth (%)----100.00%----+473.02%+33.94%
Cost of Revenue2.00K23.00K141.00K974.00K1.85M2.77M4.05M3.09M20.06M28.77M
Gross Profit-2.00K-23.00K886.00K-974.00K-1.85M-2.77M-4.05M47.60M270.45M360.36M
Gross Margin--86.27%----93.90%93.09%92.61%
Operating Expense1.14M4.75M12.80M21.11M31.15M65.51M141.14M157.33M204.76M199.06M
Operating Income-1.14M-4.77M-11.92M-22.08M-33.00M-68.28M-145.20M-109.73M65.69M161.29M
Operating Margin---1160.27%-----216.43%22.61%41.45%
EBITDA-1.14M-4.63M-10.75M-18.11M-30.32M-65.31M-116.14M-92.22M109.91M196.02M
EBITDA Margin---1046.54%-----181.90%37.83%50.37%
Net Income-1.15M-7.92M-10.89M-19.09M-32.17M-69.57M-139.97M10.93M89.16M204.83M
Net Income Margin---1060.27%----21.56%30.69%52.64%
R&D741.00K3.21M7.76M15.62M17.94M27.88M42.46M46.43M53.57M58.05M
R&D as % of Total Revenue--755.70%----91.58%18.44%14.92%
Interest Expense7.00K3.15M1.03M0832.00K1.49M5.22M0--
Interest Expense % of Total Revenue--100.00%----0.00%--

Balance Sheet

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets2.18M50.11M116.12M209.02M310.84M626.29M558.45M818.36M1.06B1.33B
Total Liabilities1.89M640.00K2.89M6.11M18.76M32.72M36.22M39.71M109.46M114.23M
Total Equity289.00K49.47M113.23M202.91M292.08M593.58M522.23M778.64M946.38M1.22B
Cash1.92M49.59M103.67M187.51M268.27M341.25M161.90M358.33M344.87M496.30M
Total Debt1.84M--3.26M11.55M8.02M8.93M8.09M7.26M9.34M
Net Debt-80.00K-49.59M-103.67M-184.25M-256.72M-333.22M-152.97M-350.23M-337.60M-486.96M

Cash Flow

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.31M-3.89M-9.45M-18.71M-26.08M-47.94M-100.57M-88.80M123.42M200.87M
Investing Cash Flow-15.00K-210.00K-10.32M-4.97M-11.18M-226.77M-114.08M82.64M-163.44M-58.42M
Financing Cash Flow3.25M51.77M73.85M107.53M118.02M347.69M35.35M202.75M27.01M8.71M
Capital Expenditure15.00K210.00K2.23M6.40M14.84M68.34M52.98M11.80M4.24M11.95M
Free Cash Flow-1.33M-4.10M-11.68M-25.11M-40.93M-116.27M-153.55M-100.60M119.18M188.91M
Dividends Paid-0--------
FCF to OCF101.14%105.40%123.65%134.20%156.91%242.55%152.68%113.29%96.57%94.05%
Dividend Paid to FCF-0.00%--------

Earnings

Report DateSep 20, 2017Nov 13, 2017Mar 12, 2018May 7, 2018Aug 6, 2018Nov 5, 2018Mar 12, 2019May 6, 2019Aug 5, 2019Nov 4, 2019Mar 10, 2020May 4, 2020Aug 10, 2020Nov 9, 2020Mar 1, 2021May 10, 2021Aug 9, 2021Nov 8, 2021Feb 28, 2022May 9, 2022Aug 8, 2022Nov 7, 2022Feb 27, 2023May 8, 2023Aug 7, 2023Nov 6, 2023Feb 26, 2024May 6, 2024Aug 5, 2024Nov 4, 2024Feb 24, 2025May 6, 2025Aug 4, 2025Nov 3, 2025Feb 17, 2026May 4, 2026Aug 3, 2026Nov 2, 2026
EPS Estimate--0.74-0.23-0.48-0.34-0.26-0.23-0.33-0.31-0.40-0.33-0.44-0.39-0.46-0.59-0.56-0.78-0.74-0.73-1.05-1.00-1.26-0.56-1.44-0.74-0.67-0.250.150.990.901.851.521.441.121.581.421.701.84
EPS Actual-0.06-1.26-0.26-0.21-0.22-0.26-0.27-0.29-0.37-0.25-0.31-0.31-0.37-0.49-0.53-0.74-0.74-0.70-0.95-0.99-1.10-1.17-1.25-1.76-1.25-0.670.960.030.930.911.531.201.292.661.701.831.792.05
Surprise--70.27%-13.04%56.25%35.29%0.00%-17.39%12.12%-19.35%37.50%6.06%29.55%5.13%-6.52%10.17%-32.14%5.13%5.41%-30.14%5.71%-10.00%7.14%-123.21%-22.22%-68.92%0.00%484.00%-80.00%-6.06%1.11%-17.39%-21.05%-10.42%137.50%7.59%28.87%5.29%11.41%
TimingAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap9.84B
Enterprise Value9.01B
Trailing P/E41.64
Forward P/E47.85
Price / Sales22.33
Price / Book7.24
EPS7.98
Book Value45.92
Revenue (TTM)440.48M
Gross Profit (TTM)416.87M
EBITDA199.29M
Profit Margin54.82%
Operating Margin49.00%
Return on Equity20.12%
Return on Assets9.37%
Shares Outstanding29.60M
Shares Float23.62M
Beta0.50
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 12 analystsTarget 395.44
  • Strong Buy
    10
  • Buy
    1
  • Hold
    1

Ownership Breakdown

Institutions
104.39%
Insiders
10.66%
Retail / Other
0.00%

Top Institutional Holders

  • FMR Inc
    4.42M14.93%
  • BlackRock Inc
    4.18M14.13%
  • venBio Select Advisor LLC
    2.89M9.76%
  • Vanguard Portfolio Management, LLC
    1.57M5.32%
  • State Street Corp
    1.35M4.56%
  • Vanguard Capital Management, LLC
    1.24M4.19%
  • Soleus Capital Management, L.P.
    939.25K3.17%
  • Capital World Investors
    777.84K2.63%
  • Vestor Capital Partners
    700.91K2.37%
  • Geode Capital Management, LLC
    698.99K2.36%
  • T. Rowe Price Associates, Inc.
    687.40K2.32%
  • Hood River Capital Management LLC
    663.38K2.24%
  • Redmile Group, LLC
    632.00K2.14%

Top Fund Holders

  • Fidelity Select Biotechnology
    1.80M6.09%
  • iShares Core S&P Mid-Cap ETF
    957.06K3.23%
  • Vanguard MStar Total Stk Mkt Idx Invest
    848.20K2.87%
  • Fidelity Growth Company Fund
    816.13K2.76%
  • American Funds SMALLCAP World A
    752.24K2.54%
  • iShares Russell 2000 ETF
    661.37K2.23%
  • Vanguard Small Cap Index
    599.36K2.02%